95
Participants
Start Date
May 20, 2014
Primary Completion Date
April 13, 2015
Study Completion Date
April 13, 2015
Belimumab autoinjector
Single use, disposable autoinjector assembled with the prefilled syringe containing the drug product belimumab with unit dose strength of 200mg/mL and 1 mL will be given as a once weekly SC dose
GSK Investigational Site, Brooklyn
GSK Investigational Site, Smithtown
GSK Investigational Site, Duncansville
GSK Investigational Site, Wyomissing
GSK Investigational Site, Beckley
GSK Investigational Site, Chapel Hill
GSK Investigational Site, Raleigh
GSK Investigational Site, Greenville
GSK Investigational Site, Charlotte
GSK Investigational Site, Charleston
GSK Investigational Site, Greenville
GSK Investigational Site, Lawrenceville
GSK Investigational Site, Orlando
GSK Investigational Site, Birmingham
GSK Investigational Site, Tuscaloosa
GSK Investigational Site, Flowood
GSK Investigational Site, Lansing
GSK Investigational Site, Oklahoma City
GSK Investigational Site, Houston
GSK Investigational Site, Houston
GSK Investigational Site, Webster
GSK Investigational Site, Phoenix
GSK Investigational Site, Phoenix
GSK Investigational Site, Mesa
GSK Investigational Site, Gilbert
GSK Investigational Site, Tustin
GSK Investigational Site, San Leandro
Lead Sponsor
GlaxoSmithKline
INDUSTRY